Early as the beginning of this century, novel molecular targeted agents like EGFR-TKIs represented by gefitinib or erlotinib, which interfere with EGFR signaling, have been proved dramatically effective for selected advanced NSCLC patients with sensitive EGFR mutations [3]. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.